Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pasteur dengue vaccine not 100% but encourages competition

This article was originally published in Scrip

Executive Summary

When Sanofi Pasteur announced in July 2012 that its recombinant dengue fever vaccine CYD-TDV had completed a Phase II study in Thailand, it came as somewhat of a surprise that the efficacy of the vaccine did not approach 100%. With the publication of the results from that trial in the 11 September issue of The Lancet, it is now clear the fly in the ointment is primarily the vaccine's lack of efficacy against the DENV2 subtype of dengue, one of four virus serotypes against which the vaccine was designed.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts